Literature DB >> 12354927

Molecular aspects of multiple myeloma.

G Pratt1.   

Abstract

Multiple myeloma is a malignant tumour of plasma cells with a median survival of two to three years. Karyotypic instability is seen at the earliest stage of the disease and increases with disease progression, leading to extreme genetic abnormalities similar to solid tumours. Translocations involving the immunoglobulin heavy chain region on chromosome 14q32 are clearly important in the pathogenesis of most myelomas. This review focuses on the different genetic abnormalities found in myeloma and discusses possible pathogenetic mechanisms and the implications for biologically based treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354927      PMCID: PMC1187254          DOI: 10.1136/mp.55.5.273

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  116 in total

1.  Hypodiploidy is a major prognostic factor in multiple myeloma.

Authors:  N V Smadja; C Bastard; C Brigaudeau; D Leroux; C Fruchart
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  R Fonseca; M M Oken; P R Greipp
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

3.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.

Authors:  G Tricot; J R Sawyer; S Jagannath; K R Desikan; D Siegel; S Naucke; S Mattox; D Bracy; N Munshi; B Barlogie
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

4.  p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance.

Authors:  G Guillerm; E Gyan; D Wolowiec; T Facon; H Avet-Loiseau; K Kuliczkowski; F Bauters; P Fenaux; B Quesnel
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

5.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Authors:  P I Croucher; C M Shipman; J Lippitt; M Perry; K Asosingh; A Hijzen; A C Brabbs; E J van Beek; I Holen; T M Skerry; C R Dunstan; G R Russell; B Van Camp; K Vanderkerken
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

6.  Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).

Authors:  J W Janssen; J W Vaandrager; T Heuser; A Jauch; P M Kluin; E Geelen; P L Bergsagel; W M Kuehl; H G Drexler; T Otsuki; C R Bartram; E Schuuring
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

7.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.

Authors:  M J Calasanz; J C Cigudosa; M D Odero; C Ferreira; M T Ardanaz; A Fraile; J L Carrasco; F Solé; B Cuesta; A Gullón
Journal:  Genes Chromosomes Cancer       Date:  1997-02       Impact factor: 5.006

8.  Karyotype in multiple myeloma and plasma cell leukaemia.

Authors:  H J Weh; K Gutensohn; J Selbach; R Kruse; G Wacker-Backhaus; D Seeger; W Fiedler; W Fett; D K Hossfeld
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

9.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells.

Authors:  M Pettersson; H Jernberg-Wiklund; L G Larsson; C Sundström; I Givol; Y Tsujimoto; K Nilsson
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

10.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

Authors:  G Tricot; B Barlogie; S Jagannath; D Bracy; S Mattox; D H Vesole; S Naucke; J R Sawyer
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

View more
  12 in total

Review 1.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

2.  Amplification of 1q21 and other abnormalities in multiple myeloma patients from a tertiary hospital in singapore.

Authors:  Alvin S T Lim; Sathish Krishnan; Tse Hui Lim; Karen See; Yit Jun Ng; Yu Min Tan; Natasha Choo; Lai Ching Lau; Sim Leng Tien; Jun Ma; Daryl Tan
Journal:  Indian J Hematol Blood Transfus       Date:  2013-09-04       Impact factor: 0.900

3.  Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance.

Authors:  Olivera Marković; D Marisavljević; V Cemerikić; A Vidović; M Perunicić; M Todorović; I Elezović; M Colović
Journal:  Med Oncol       Date:  2008-05-01       Impact factor: 3.064

4.  Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.

Authors:  O Markovic; D Marisavljevic; V Cemerikic; N Suvajdzic; N Milic; M Colovic
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

5.  Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.

Authors:  Liat Josefsberg Ben-Yehoshua; Katia Beider; Avichai Shimoni; Olga Ostrovsky; Michal Samookh; Amnon Peled; Arnon Nagler
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

6.  Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.

Authors:  Sean Bujarski; Kyle Udd; Camilia Soof; Haiming Chen; Tanya M Spektor; Tahmineh Safaie; Mingjie Li; Joshua Stern; Cathy Wang; Ning Xu; Marsiye Emamy-Sadr; Regina Swift; Ashkon Rahbari; Saurabh Patil; Eric Souther; Bernard Regidor; Christine Sutanto; James R Berenson
Journal:  Target Oncol       Date:  2021-06-07       Impact factor: 4.493

7.  BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.

Authors:  L Bolkun; D Lemancewicz; E Jablonska; A Kulczynska; U Bolkun-Skornicka; J Kloczko; J Dzieciol
Journal:  Ann Hematol       Date:  2013-10-19       Impact factor: 3.673

Review 8.  Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma.

Authors:  Rendong Yang; Li Chen; Scott Newman; Khanjan Gandhi; Gregory Doho; Carlos S Moreno; Paula M Vertino; Leon Bernal-Mizarchi; Sagar Lonial; Lawrence H Boise; Michael Rossi; Jeanne Kowalski; Zhaohui S Qin
Journal:  Cancer Inform       Date:  2014-09-21

Review 9.  Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

Authors:  M A Dimopoulos; X Leleu; A Palumbo; P Moreau; M Delforge; M Cavo; H Ludwig; G J Morgan; F E Davies; P Sonneveld; S A Schey; S Zweegman; M Hansson; K Weisel; M V Mateos; T Facon; J F S Miguel
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

10.  Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma.

Authors:  Cristina Mansilla; Elena Soria; Miren Vallejo; Alberto Valiente; Aránzazu Perez-Juana; Amaya Zabalza; Guillermina Hurtado; Francisco Sala; Natalia Ramírez
Journal:  Transl Oncol       Date:  2018-03-30       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.